ReviewAnti-cancer agents in medicinal chemistry2011
Therapeutic potential of targeting glypican-3 in hepatocellular carcinoma.
Review in Anti-cancer agents in medicinal chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Prognostic and clinicopathological significance of glypican-3 overexpression in hepatocellular carcinoma: a meta-analysis.World journal of gastroenterology · 2014Pooled it
- MicroRNA-1303 in cancer pathogenesis and therapy: clinical implications for biomarker development and targeted treatment strategies.Cancer cell international · 2025Review
- Diagnostic and Prognostic Value of Protein Post-translational Modifications in Hepatocellular Carcinoma.Journal of clinical and translational hepatology · 2023Review
- The extracellular matrix in hepatocellular carcinoma: Mechanisms and therapeutic vulnerability.Cell reports. Medicine · 2023Review
- Proteoglycans in Cancer: Friends or Enemies? A Special Focus on Hepatocellular Carcinoma.Cancers · 2022Review
- Imaging ligands targeting glypican-3 receptor expression in hepatocellular carcinoma.American journal of nuclear medicine and molecular imaging · 2022Review
- Therapeutic efficacy of aJournal of traditional and complementary medicine · 2021Article
- Value of miR-1271 and glypican-3 in evaluating the prognosis of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization.World journal of clinical cases · 2020Article
- Significance of Glypican-3 in Early Detection of Hepatocellular Carcinoma in Cirrhotic Patients.Journal of gastrointestinal cancer · 2019Article
- Expression of oncofetal antigen glypican-3 associates significantly with poor prognosis in HBV-related hepatocellular carcinoma.Oncotarget · 2016Article
- Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma.Cancer biomarkers : section A of Disease markers · 2016Article
- Wnt-/-β-catenin pathway signaling in human hepatocellular carcinoma.World journal of hepatology · 2015Article
- Primary colon cancer with a high serum PIVKA-II level.International journal of surgery case reports · 2015Article
- Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma.Journal of hepatocellular carcinoma · 2014Review
- An introduction to proteoglycans and their localization.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2012Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Glypican-3 (GPC3) is a developmentally-regulated oncofetal protein that has been established as a clinically-relevant biomarker for early hepatocellular carcinoma (HCC). It is one of the first transcripts to appear during malignant hepatocyte transformation, and is expressed at the protein level in approximately half of high-grade dysplastic macronodules in cirrhotic liver. Several studies show it is expressed in most (75 to 100%) of HCCs confirmed by histopathology. The protein is anchored to the hepatocyte membrane by a glycosyl-phosphatidylinositol (GPI) anchor and shows consistent membrane immunostaining pattern, making it a viable target for immunotherapeutic approaches. Targeting GPC3 for therapeutic intervention is a promising approach for the clinical management of HCC and selected other tumors that express the marker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.